Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2014-04-09 Share Issue/Capital Cha…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Share Issue/Capital Change Classification · 99% confidence The document is dated April 9, 2014, and announces that Ipsen is eligible for the PEA-PME scheme and has been admitted to the CAC® PME index by Euronext. It provides company background, financial context (2013 sales), R&D focus, and includes extensive forward-looking statements and contact information for media and investors. This content structure—a press release announcing a specific corporate event (index inclusion/eligibility) alongside general company information and risk warnings—is characteristic of a general corporate announcement. Since it is not a formal regulatory report (like 10-K, IR, or ER), nor a specific filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a public disclosure of a material corporate event.
2014-04-09 French
Communicated under the obligation to provide permanent information / Other communications
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated March 20, 2014, announcing a significant transaction involving the controlling shareholder (Mayroy) selling shares and Ipsen repurchasing 1% of its own shares for cancellation. This directly relates to changes in share capital structure and transactions involving the company's own stock. The key phrases are 'Mayroy, its controlling shareholder, had completed an institutional private placement of... shares' and 'Ipsen purchased 842 542 of its own shares (representing 1% of its share capital) to be cancelled.' This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance, and also touches upon 'Share Issue/Capital Change' (SHA). However, the primary action described is the company buying back its own shares, making POS the most specific fit. It is not a full 10-K, an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2014-03-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Major Shareholding Notification Classification · 99% confidence The document is a press release from Ipsen dated March 20, 2014, announcing a significant transaction involving its majority shareholder, Mayroy, selling shares (a private placement) and Ipsen buying back 1% of its own capital for cancellation. This directly relates to changes in share capital structure, share ownership, and transactions involving the company's own stock. The key elements are: 1) Sale of shares by a major shareholder (affecting ownership/float), 2) Ipsen buying back its own shares for cancellation (share repurchase), and 3) Renewal of an existing shareholder agreement. This combination strongly points towards corporate actions related to capital structure and share transactions. The most fitting categories are 'Share Issue/Capital Change' (SHA) or 'Transaction in Own Shares' (POS). Since the primary action described is the major shareholder selling shares (which increases the free float) and the company simultaneously executing a buyback/cancellation, 'Transaction in Own Shares' (POS) covers the buyback aspect, while 'Share Issue/Capital Change' (SHA) covers the overall capital structure shift and major ownership change. Given the explicit mention of Ipsen buying back its own shares ('Ipsen a procédé au rachat de 842 542 de ses propres actions (soit 1% de son capital) afin de les annuler'), POS is highly relevant. However, the overall context is a major change in the capital structure driven by the majority shareholder's divestment and the subsequent float increase. SHA covers capital structure changes more broadly. Since the document details both a major shareholder transaction affecting the float AND the company's own share repurchase, SHA (Share Issue/Capital Change) is a slightly broader and appropriate fit for the overall event, although POS is also strongly indicated by the buyback. Given the context of major ownership changes and capital structure adjustments, SHA is selected as the primary classification.
2014-03-20 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2014, announcing positive results from a Phase IIa clinical study for Dysport® in treating neurogenic detrusor overactivity (NDO). It details efficacy data, quotes R&D leadership, provides background on the drug and the condition, and includes standard forward-looking statements and contact information. This format—a formal announcement of specific periodic or trial results, often released before a full regulatory filing or quarterly report—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical milestones. Since it focuses on announcing financial/operational results (clinical trial success impacting future revenue potential) rather than being a comprehensive financial report (10-K, IR) or a transcript (CT), the best fit among the provided options is 'Earnings Release' (ER), as these releases often contain key operational highlights that drive investor interest, even if they aren't strictly quarterly earnings figures. It is not a Call Transcript, Audit Report, or a simple Report Publication Announcement (RPA) because it contains substantial content about the results themselves, not just a notice that a report is available.
2014-03-18 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated March 18, 2014, announcing positive results from a Phase IIa clinical study for the drug Dysport® in treating Neurogenic Detrusor Overactivity (NDO). It details efficacy, safety, background information on the drug and the condition, and includes forward-looking statements and contact information for media/investors. This content structure—a formal announcement of clinical trial results and business updates—is characteristic of an Earnings Release (ER) or a general press release that is not a full financial report (10-K, IR) or a transcript (CT). Since it is focused on announcing specific, material operational/R&D news (clinical trial success) rather than just financial figures, it aligns best with the 'Earnings Release' category, which often encompasses major operational announcements made outside of formal quarterly filings, or it could be classified as a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on announcing a key development (clinical results) which often precedes or accompanies financial reporting periods, ER is a strong fit, although RNS is a possibility. However, ER is typically used for material operational news releases. Since it is not a full financial report (10-K or IR), and it is a direct announcement of results, ER is the most appropriate specific category over the general RNS fallback.
2014-03-18 English
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 95% confidence The document explicitly states it provides 'Monthly information regarding the total number of voting rights and total number of shares of the Company' based on Article 223-16 of the AMF General Regulations. This content—a periodic update on the total number of shares and voting rights—does not fit neatly into the primary financial report categories (10-K, IR) or specific event categories (DIV, DIRS, ER). It is a mandatory regulatory disclosure concerning capital structure and voting power. Since there is no specific code for 'Voting Rights/Share Count Update', the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a standard, periodic regulatory disclosure.
2014-03-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.